|  | Wnt8 (50 ng/μl) | Wnt5 (50 ng/μl) |
|---|
Co-injected mRNA | n | Percentage of embryos showing a reduced forebrain | n | Percentage of embryos showing a reduced forebrain |
|---|
None (Wnt8/Wnt5 alone) | 107 | 88 | 81 | 86 |
Sfrp1 (200 ng/μl) | 81 | 0 (30) | 78 | 0 (90) |
Sfrp1
CRD
(100 ng/μl) | 68 | 96 | 72 | 83 |
Sfrp1
NTR
(120 ng/μl) | 110 | 20 (14) | 90 | 7 (60) |
Sfrp3 (200 ng/μl) | 96 | 87 | 98 | 69 |
Sfrp3
CRD
(120 ng/μl) | 117 | 92 | 81 | 93 |
Sfrp3
NTR
(100 ng/μl) | 94 | 60 | 89 | 72 |
- Percentage of embryos showing a size reduction of the forebrain/optic vesicles upon injection of equimolecular amounts of mRNAs encoding Wnt8 or Wnt5 together with different variants of Sfrp1 and Sfrp3 mRNAs. Representative embryos are shown in Figure 2 and Additional file 2. Wnt8-induced forebrain reduction is much more severe (optic vesicles are completely absent), than that observed upon wnt5 over-expression, where the optic vesicles are, in general, significantly reduced in size but still visible. In the case of Wnt and Sfrp1 and Sfrp1
NTR
co-injections, the number shown in brackets represents the frequency of appearance of the anteriorised phenotype (enlarged forebrain tissue), which is reduced compared to the over-expression of the given Sfrp construct alone (Table 1).
